Drugs & Targets Jaypirca receives FDA accelerated approval for R/R mantle cell lymphoma February 03, 2023Vol.49 No.05
Drugs & Targets Orserdu & companion diagnostic for ER+, HER2-, ESR1-mutated advanced breast cancer receive FDA approval February 03, 2023Vol.49 No.05
Drugs & Targets RefleXion receives FDA clearance for SCINTIX biology-guided radiotherapy February 03, 2023Vol.49 No.05
Drugs & Targets FLAG Therapeutics’s FLAG-003 receives Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma February 03, 2023Vol.49 No.05
Drugs & Targets AstraZeneca, Thermo Fisher to develop develop solid tissue and blood-based companion diagnostic for Tagrisso January 27, 2023Vol.49 No.04
Drugs & Targets AstraZeneca, Ibex collaborate on AI-powered HER2 scoring product January 27, 2023Vol.49 No.04
Drugs & Targets Evotec, Janssen collaborate to develop immune-based therapies January 27, 2023Vol.49 No.04
Drugs & Targets Tukysa + trastuzumab receives FDA accelerated approval for previously treated metastatic CRC January 20, 2023Vol.49 No.03
